INDVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Indivior Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$33.87+1.42 (+4.38%)
Close on Oct 19, 2026
- Market cap
- $4.20B
- P/E (TTM)
- 12.2
- Dividend yield
- –
Indivior Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 82.1%
- Operating margin
- 31.6%
- Net margin
- 26.7%
- Return on equity, FY2025
- -96.6%
Financial strength
- Current ratio
- 0.84
- Debt to equity
- -2.34
- Debt to assets
- 39.5%
- Cash to current liabilities
- 25.6%
Valuation
- P/E ratio
- 12.2
- Price to sales
- 3.15
- Price to book
- –
- Dividend yield
- –